ClinicalTrials.gg
Status unknownNCT01149161Updated Apr 21, 2016

Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma

A Phase 2/3 interventional study of Routine central neck dissection in Carcinoma, sponsored by Samsung Medical Center. Status unknown at 1 site in South Korea. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-21.

Sponsored by Samsung Medical Center · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Occult lymph node metastasis is common in micro papillary thyroid cancer. However, the role of lymph node dissection in the treatment of microPTC remains controversial. The investigators want to investigate the usefulness routine central dissection and sentinel lymph node biopsy in prognosis of micro PTC. This is a prospective randomized control study. The investigators started this study from May of 2009 and this study will be continued until Dec. 2011.

Read the detailed description

The investigators will assign all patients to three groups; no dissection group (Group I), sentinel lymph node biopsy only group (Group II) and routine central neck dissection group (Group III). At first, to know the necessity of routine central neck node dissection for micro PTC,the investigators will compare the result of group I and group III. Additionally, the investigators can analyze the usefulness of sentinel lymph node biopsy for substitution of routine central neck node dissection for micro PTC.

02

Conditions studied

  • Carcinoma

Keywords

  • neck dissection
  • sentinel lymph node
  • Carcinoma
  • Papillary
  • thyroid
  • dissection
03

In context

Carcinoma

6,719 studies on the registry are indexed under Carcinoma; 1,142 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 45 across 5,153 interventional studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Samsung Medical Center is the lead sponsor of 1,005 studies on the registry; 148 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • papillary carcinoma of thyroid (less than 4cm)
  • no evidence of lymph node metastasis in preoperative work-up result
  • the patients who accept this study

Exclusion criteria

Exclusion Criteria:

  • large thyroid cancer( > 4cm)
  • morbid
  • anticoagulation agent usage
  • endoscopic or robotic thyroid operation
  • evidence of lymph node metastasis or extrathyroidal extension in preoperative US and CT scan
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    C group

    Routine central neck dissection

    Procedure: Routine central neck dissection

  • No intervention
    N group

    No central neck node dissection

Interventions

  • ProcedureRoutine central neck dissection

    Level VI neck node dissection during thyroid operation

06

What researchers measure

Primary outcomes

  1. Is routine neck node dissection necessary in micro PTC?

    To see the necessity of routine neck node dissection in micro PTC, we will compare the recurrence rate and other complication (e.g. hoarseness and hypocalcemia) between group I(no dissection) and group III(routine dissection) after completion of study(after 5 year f/u). To check the safety of this study, our result will be checked by korea institutional reveiw board every one year.

    Time frame: Until 5 year follow-up. (Dec. 2016)

Secondary outcomes

  1. The efficacy of sentinel lymph node biopsy in micro PTC

    Time frame: Until 5 year follow-up. (Dec. 2016)

07

Study locations

1 of 1 sites recruiting
  • Samsung Medical Center
    Seoul, 135-710, South Korea
    • Jee Soo Kim, M.D., Ph.D. · Contact · 82-2-3410-3479
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01149161
Responsible party
Jee soo Kim (Associate professor, Samsung Medical Center) — Principal investigator
First posted
Jun 23, 2010
Start date
May 2009
Primary completion
Dec 2017 (estimated)
Completion
Dec 2020 (estimated)
Last update
Apr 21, 2016

Study contacts

Jee Soo Kim, M.D., Ph.D.
Contact
js0507.kim@samsung.com
82-2-3410-3479
Jee Soo Kim, M.D., Ph.D.
study chair · Samsung Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion